Prosecution Insights
Last updated: August 16, 2026
Application No. 17/786,239

SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS

Non-Final OA §112
Filed
Jun 16, 2022
Priority
Dec 23, 2019 — IN 201911053557 +1 more
Examiner
SAMSELL, RILLA MARIE
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bristol-Myers Squibb Company
OA Round
3 (Non-Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
59 granted / 82 resolved
+12.0% vs TC avg
Moderate +15% lift
Without
With
+15.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
32 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
7.6%
-32.4% vs TC avg
§103
24.3%
-15.7% vs TC avg
§102
21.8%
-18.2% vs TC avg
§112
31.7%
-8.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 82 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Request for Continued Examination A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04/14/2026 has been entered. Status of the Claims Claims 1-12 and 18-20 are pending. Acknowledgment is made of the amendment of claims 1, 2, and 19 in the reply filed 04/14/2026. Withdrawn Rejections Applicant’s amendment to the claims, filed 04/14/2026, overcomes the rejection of claims 1, 2, 6, 7, 10, 12, 18, and 19 under 35 U.S.C. 102(a)(1) as being unpatentable over Santilli (U.S. 4,284,768 A). The rejection of claims 1, 2, 6, 7, 10, 12, 18, and 19 has been withdrawn. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 11 and 20 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 11 teaches compound 6, in which the R1 variable of Formula (I) is H. Claim 20 teaches compounds 9, 11, 13, 14, 15, and 16, in which the R1 variable Formula (I) is H. However, claim 1, from which claim 11 and 20 depend, teaches that R1 may only be F, Cl, Br, CN, C1-3 alkyl substituted with zero to 4 R1a, C3-4 cycloalkyl substituted with zero to 4 R1a, C1-3 alkoxy substituted with zero to 4 R1a,-C(O)NRaRa, -NRaRa, -S(O)nRe, or -P(O)ReRe. Therefore, claims 11 and 20 fail to include all the limitations of the claim upon which they depend. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1-10, 12, 18, and 19 are allowed. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a). Conclusion Claims 11 and 20 are rejected. Claims 1-10, 12, 18, and 19 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RILLA M SAMSELL whose telephone number is (703)756-5841. The examiner can normally be reached Monday-Friday, 7-3. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.M.S./Examiner, Art Unit 1624 /JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 16, 2022
Application Filed
Jun 03, 2025
Non-Final Rejection mailed — §112
Aug 26, 2025
Response Filed
Oct 16, 2025
Final Rejection mailed — §112
Apr 14, 2026
Request for Continued Examination
Apr 19, 2026
Response after Non-Final Action
Jun 03, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697344
THERAPEUTIC COMPOSITIONS, COMPONENTS AND METHODS OF PREPARATION AND USE THEREOF
3y 4m to grant Granted Aug 04, 2026
Patent 12679838
AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG
3y 5m to grant Granted Jul 14, 2026
Patent 12679848
PLASMA KALLIKREIN INHIBITORS
3y 2m to grant Granted Jul 14, 2026
Patent 12673927
SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION
3y 8m to grant Granted Jul 07, 2026
Patent 12668589
N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF
3y 9m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
87%
With Interview (+15.0%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 82 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month